Cited by 220Cell Adhesion Molecules ResearchEffects of Radiation ExposurePI3K/AKT/mTOR signaling in cancer

β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts

Open access

Abstract

β1 Integrin signaling has been shown to mediate cellular resistance to apoptosis after exposure to ionizing radiation (IR). Other signaling molecules that increase resistance include Akt, which promotes cell survival downstream of β1 integrin signaling. We previously showed that β1 integrin inhibitory antibodies (e.g., AIIB2) enhance apoptosis and decrease growth in human breast cancer cells in three-dimensional laminin-rich extracellular matrix (lrECM) cultures and in vivo. Here, we asked whether AIIB2 could synergize with IR to modify Akt-mediated IR resistance. We used three-dimensional lrECM cultures to test the optimal combination of AIIB2 with IR treatment of two breast cancer cell lines, MCF-7 and HMT3522-T4-2, as well as T4-2 myr-Akt breast cancer colonies or HMT3522-S-1, which form normal organotypic structures in three-dimensional lrECM. Colonies were assayed for apoptosis and β1 integrin/Akt signaling pathways were evaluated using Western blot. In addition, mice bearing MCF-7 xenografts were used to validate the findings in three-dimensional lrECM. We report that AIIB2 increased apoptosis optimally post-IR by down-regulating Akt in breast cancer colonies in three-dimensional lrECM. In vivo, addition of AIIB2 after IR significantly enhanced tumor growth inhibition and apoptosis compared with either treatment alone. Remarkably, the degree of tumor growth inhibition using AIIB2 plus 2 Gy radiation was similar to that of 8 Gy alone. We previously showed that AIIB2 had no discernible toxicity in mice; here, its addition allowed for a significant reduction in the IR dose that was necessary to achieve comparable growth inhibition and apoptosis in breast cancer xenografts in vivo. [Cancer Res 2008;68(11):4398–405]

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-6390

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Antibodies against integrins β1, β6 and β8 selectively impair TGF-β1 activation.

    “Antibodies against integrins β1, β6 and β8 were shown to selectively impair TGF-β1 activation85,313–315”

    From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [315]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., & Bissell, M. J.
Affiliations
  • University of California, San Francisco (US)
  • Lawrence Berkeley National Laboratory (US)
Venue
Cancer Research
Published
2008-06-01
Volume
68
Issue
11
Pages
4398-4405
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1968324001
Cited by
220
References
43
Citations by year
2026: 6 · 2025: 3 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 9 · 2019: 10 · 2018: 12 · 2017: 14 · 2016: 13 · 2015: 13 · 2014: 20 · 2013: 19 · 2012: 18
FWCI
8.20
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • University of North Texas Digital Library (University of North Texas) (submittedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
Funders
  • U.S. Department of Defense (DE-AC02-05CH11231)
  • U.S. Department of Energy (-AC02-05CH11231, DE-AC03-?, AC03-76SF00098, DEAC03-76SF00098, 05CH11231, DE AC02 05CH11231, DE-AC02-)
  • National Institutes of Health (DE-AC02–05CH11231, NIH P50, DE-AC03- 76SF00098)
  • University of California, San Francisco
  • National Cancer Institute (R01CA124891, CA64786-09, CA-58207, R37CA064786, P50CA058207, R01CA064786, CA CA58207-08, DE-AC02-05CH11231)
  • Biological and Environmental Research (05CH11231, DE-AC02 − 05CH11231, AC02-05CH11231)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
beta1 integrin, radiotherapy, breast cancer, Akt signaling, radioresistance (biology), apoptosis, MCF-7 xenografts, tumor growth inhibition, radiosensitization
MeSH terms
Breast, Breast Neoplasms, Cell Line, Cell Separation, Humans, Transplantation, Heterologous, Blotting, Western, Treatment Outcome, Apoptosis, Microscopy, Confocal, Integrin beta1, In Situ Nick-End Labeling, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review